
Roche Phase III study misses COVID-19 endpoint
In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...

EU orders 100 million additional doses from Biontech
To avoid supply shortages that could occur as a result of restricted use of adenoviral COVID-19 vaccines, the European Commission has acquired...

Italian Enthera Pharma raise €35m in Series A extension
Roche Venture Fund joined seed investor Sofinnova Partners and AbbVie Ventures and co-investors including the JDRF T1D Fund, an investor group...

Bispecific IgG switch off SARS-CoV-2 escape variants
The team headed by Daniel Ruzek or Luca Varani from the University of Bellinzona and the Czech Academy of Sciences targeted two binding sites within...

InteRNA Technologies secures €18.5m in Series B financing
Waterman Ventures and current shareholders Aglaia Oncology Funds and OostNL participated in the funding. The Utrecht-based...

Oxular Ltd raises US$37m
Oxford-based Oxular said it will use the proceeds to finance Phase II studies evaluatingO the company’s lead asset, OXU-001, for the treatment of...

LSP reports first closing of dementia fund
The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...